Engineering T cells with hypoxia-inducible chimeric antigen receptor (HiCAR) for selective tumor killing

Chimeric antigen receptor-modified T cells (CAR-T cells) have shown good effects in the treatment of hematologic cancers; however, they may cause on-target off-tumor toxicity because of minimal expression of tumor-associated antigens (TAAs) on normal tissues, particularly in the context of treating...

Descripción completa

Detalles Bibliográficos
Autores principales: Liao, Qibin, He, Huan, Mao, Yunyu, Ding, Xiangqing, Zhang, Xiaoyan, Xu, Jianqing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7602323/
https://www.ncbi.nlm.nih.gov/pubmed/33292642
http://dx.doi.org/10.1186/s40364-020-00238-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7602323/
https://www.ncbi.nlm.nih.gov/pubmed/33292642
http://dx.doi.org/10.1186/s40364-020-00238-9

Ejemplares similares